Waypoint Bio raises $20M to run three CAR-T trials in China
New York City-based startup Waypoint Bio has raised $20 million in Series A financing to test multiple cell therapies in China, the company told Endpoints News....
New York City-based startup Waypoint Bio has raised $20 million in Series A financing to test multiple cell therapies in China, the company told Endpoints News. The move takes advantage of China's system for testing ...